SMARCA4 and neuroblastoma: Clinical NB cases with up‐regulation of KPNB1, CNBP, SMARCC1, SMARCA4 or down‐regulation of SMARCC2 have poor survival and prognosis, indicating KPNB1/CNBP/SMARCC2 axis as a valuable target for therapeutics of tumours.